IGF1-LR3 INJECTOR PEN 3ML 100MCG

IGF1-LR3: The Extended‑Activity Growth‑Factor Analog for Advanced Anabolic Signaling, Tissue Remodeling, and Metabolic Research

In the evolving landscape of peptide and growth‑factor science, IGF‑1 LR3 (also referenced in the literature as Long‑(Arg3) insulin‑like growth factor‑I or LR3IGF‑I) stands out as a recombinant IGF‑1 analog engineered to deliver stronger, more sustained biological activity in systems where native IGF‑1 is rapidly neutralized by IGF‑binding proteins (IGFBPs). The defining structural features commonly cited for IGF‑1 LR3 include an arginine substitution at amino acid 3 plus an additional 13‑amino‑acid N‑terminal extension, modifications associated with reduced IGFBP affinity, longer functional exposure, and increased potency relative to native IGF‑1 in multiple research settings.

At a signaling level, IGF‑1 biology is tightly linked to IGF‑1 receptor (IGF‑1R) activation, which can engage growth and survival cascades such as PI3K/Akt and Raf/MEK/ERK, influencing proliferation, survival, differentiation, and nutrient handling.

Because IGF‑1 LR3 is a research‑focused analog (and UNII listing does not imply regulatory approval), it is best positioned as a tool for mechanistic studies—for example, catabolic physiology, cell‑culture productivity, tissue growth/remodeling endpoints, and neurobiology models where insulin/IGF signaling is under investigation.

Five Research‑Backed Benefits and Use‑Cases

1) Amplified anabolic and anti‑catabolic activity in catabolic physiology models

IGF‑1 LR3 is repeatedly described in preclinical literature as a more potent IGF‑1 variant in catabolic settings, particularly when endogenous binding proteins would be expected to limit native IGF‑1 distribution to tissues.

In a classic glucocorticoid catabolism model, IGF‑1 and IGF‑1 variants were evaluated in dexamethasone‑treated rats. The authors reported that IGF‑1 administration partially reversed the catabolic state, improving outcomes such as body weight and nitrogen retention. Notably, the paper states that LR3IGF‑I (and des(1‑3)IGF‑I), which bind poorly to IGFBPs, were ~2.5‑fold more potent than IGF‑I in that model—an effect interpreted in the context of IGFBP dynamics during dexamethasone exposure.

A follow‑on study explicitly using continuous LR3IGF‑I infusion compared “early” vs “delayed” initiation relative to dexamethasone catabolism. The abstract reports that early LR3IGF‑I treatment produced substantially better nitrogen balance, carcass nitrogen gain, and protein fractional synthesis rates, with reduced fractional breakdown rates—underscoring why the analog is often viewed as a high‑signal tool for catabolic research designs.

Why it matters in research: when you need a robust “IGF signal” under IGFBP‑rich or catabolic conditions, LR3‑type analogs are frequently chosen to improve effect size and interpretability for anabolic/anti‑catabolic endpoints.

2) Reduced IGFBP binding for higher functional bioavailability and stronger downstream signaling

A central rationale for IGF‑1 LR3 is the IGFBP problem: in many biological fluids and cell systems, IGFBPs bind IGF‑1 and modulate (or limit) receptor interaction.

A peer‑reviewed review describing modified IGF‑1 forms notes that IGF‑1 LR3 includes an Arg substitution at position 3 and an added 13 amino acids at the N‑terminus, and that this modification is associated with a significantly longer half‑life, much lower affinity for IGFBPs, and ~3‑fold increased potency.

Preclinical work further supports this design logic. In the dexamethasone rat study above, LR3IGF‑I is explicitly described as an IGF‑I variant with an N‑terminal extension plus arginine at residue 3, and the authors connect the higher potency of IGF variants to the way increased IGFBPs would be expected to restrain native IGF‑I distribution more than the variants.

Why it matters in research: reduced IGFBP affinity can translate into more consistent receptor engagement and clearer dose‑response behavior in systems where IGFBPs confound native IGF‑1.

3) Gastrointestinal trophic effects and selective tissue growth responses in animal models

IGF‑1 LR3 has a particularly strong footprint in GI growth and epithelial proliferation research, where investigators often need a growth factor that reliably drives measurable changes over short windows.

A PubMed‑indexed study in Gut reports that it had previously been shown that long‑term administration of IGF‑I or LR3IGF‑I selectively stimulates growth of the gastrointestinal tract in several rat contexts, and the paper examines short‑term effects. In the reported three‑day infusion experiment, the abstract states LR3IGF‑I (but not IGF‑I) increased body weight and wet tissue weight of the small and large intestine (about +20%), with associated histological changes such as increased crypt lengths and crypt cell numbers—supporting the idea that LR3IGF‑I can induce proliferative events more rapidly than native IGF‑I in that setting.

Separately, a Journal of Endocrinology paper studying guinea pigs describes LR3IGF‑I as an analogue with much reduced affinities for IGF binding proteins and reports that, while overall growth was not stimulated, fractional weights of several tissues (including adrenals, gut, kidneys, and spleen) were significantly increased by LR3IGF‑I—useful for organ‑specific growth/remodeling and endocrine distribution questions.

Why it matters in research: LR3‑type analogs can be used to probe tissue‑selective growth responses, GI epithelial kinetics, and trophic remodeling while minimizing the interpretive noise introduced by IGFBP sequestration.

4) High‑efficiency growth and survival factor for serum‑free mammalian cell culture and bioprocessing

IGF‑1 LR3 is not only a physiological research tool—it is also well represented in serum‑free cell culture contexts where insulin is traditionally used but may be suboptimal.

A PubMed‑indexed paper in Molecular Biotechnology describes LONG R3IGF‑I as specifically engineered for use in biopharmaceutical protein production. The abstract reports that it can support CHO cell growth and survival in serum‑free media at concentrations at least 200‑fold lower than required for insulin, and that it can act as a more potent growth and survival factor than insulin or native IGF‑I in serum‑free HEK293 culture. Importantly, the authors also discuss mechanistic signaling: the mitogens tested activated IGF‑IR and insulin receptor (IR) in a dose‑responsive manner, with LR3IGF‑I producing greater activation at lower concentrations.

Why it matters in research and manufacturing: when optimizing serum‑free or low‑serum systems, IGF‑1 LR3 can be framed as a high‑potency lever for viability, density, and productivity, especially where IGF‑IR–mediated survival signaling is desired.

5) Emerging CNS and neurodegeneration research, including intranasal delivery paradigms

IGF‑1 signaling is increasingly investigated in the context of neuroinflammation, amyloid biology, and aging‑related changes in insulin/IGF pathways.

A recent open‑access PMC paper evaluates longitudinal intranasal LR3‑IGF‑1 treatment in male 5XFAD mice (an Alzheimer’s disease model). The authors report that intranasal LR3‑IGF‑1 remodeled amyloid plaque features in cerebral cortex, including reductions in certain plaque characteristics and shifts toward more “inert” plaque morphology, along with reductions in some soluble low‑molecular‑weight Aβ oligomer measures in cortex. The same paper is explicit that, despite plaque remodeling signals, the intervention did not preserve or improve measured cognitive outcomes in that study, emphasizing that these findings are mechanistic and model‑specific, not clinical efficacy.

Why it matters in research: LR3‑IGF‑1 is being used to interrogate how raising IGF signaling interfaces with microglial activation, plaque compaction, and downstream pathway readouts in CNS disease models—an area where delivery route and tissue distribution are often the limiting variables.

Metabolic and endocrine considerations for experimental design

Because IGF‑1 LR3 is engineered for higher functional potency, it can produce strong systemic metabolic signals—useful experimentally, but important for safety interpretation and confound control.

• Hypoglycemia potential (preclinical): A comparative study examining IGF‑I and several IGF‑I variants (including LR3IGF‑I) reports that the variants were consistently ~2–3× more potent than IGF‑I for lowering plasma glucose and that glucose suppression could be more prolonged (greater cumulative hypoglycemic effect over hours).

• GH/IGF axis feedback (species‑dependent): In finisher pigs, a 4‑day LR3IGF‑I infusion decreased average daily gain and feed intake and was associated with suppressed plasma GH patterns and reduced plasma IGFBP‑3, IGF‑I, and insulin, with plasma glucose reported as unaffected by treatments in that study.

• Mitogenic signaling context: IGF‑1/IGF‑1R signaling is widely recognized as central to growth and survival pathways and is also discussed in the literature as relevant to cancer biology due to roles in survival and proliferation of malignant cells—an important lens when interpreting proliferation endpoints in vitro and in vivo.

Scientific studies and links (PubMed / PMC)

Disclaimer: The summaries above describe findings from published scientific studies and are provided for educational and research‑discussion purposes only. They are not intended to diagnose, treat, cure, or prevent any disease, and they are not a substitute for medical advice.